Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Sun2.7
Sunifiram (DM-235) – Forschung
Überwiegend Mechanismus / Beobachtung
5 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Sunifiram (DM-235) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 2002–2013.
Basierend auf 5 Studien
Konfidenz
Geringe Konfidenz
Nach Outcome
Memory & cognition (rodent only, unproven in humans)Ampakin-artige AMPA-Potenzierung und Aktivierung der NMDA-Glycin-Bindungsstelle verbessern Gedächtnis/Kognition ausschließlich bei Nagetieren; beim Menschen UNBELEGT, ohne jegliche Daten zu Wirksamkeit oder Sicherheit am Menschen. · Nicht etabliert (keine Humandaten)
Überwiegend Mechanismus / Beobachtung5 Studien
Focus & mental clarity (extrapolated, unproven for sunifiram)Fokus/geistige Klarheit sind für Sunifiram extrapoliert und unbelegt; berichtet werden Überstimulation, Angstzustände, Kopfschmerzen und Schlaflosigkeit sowie das Risiko einer Identitätsverwechslung auf dem Graumarkt. · Nicht etabliert (keine Humandaten)
These results indicate that DM235, a compound structurally related to piracetam, is a novel nootropic endowed with the capability to prevent cognitive deficits at very low doses. Indeed, its potency is about 1,000 times higher than that of the most active piracetam-like compounds.
Ghelardini C, Galeotti N, Gualtieri F, Romanelli MN, Bucherelli C, Baldi E, Bartolini A. · Naunyn-Schmiedeberg's Archives of Pharmacology (2002)
FOUNDATIONAL, RODENT-ONLY: the first pharmacological characterization of DM-235 (sunifiram), a piracetam-related nootropic, in mice and rats — no human subjects
Prevented scopolamine-, mecamylamine-, baclofen- and clonidine-induced amnesia in the mouse passive-avoidance test, and reversed scopolamine-impaired Morris water-maze learning in rats, implicating cholinergic and other systems
Active at extraordinarily low doses (0.001–0.1 mg/kg i.p. or 0.01–0.1 mg/kg p.o.), roughly 1,000-fold more potent than piracetam-like compounds, without impairing motor coordination or spontaneous activity
Taken together, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCα activation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation.
The spatial reference memory assessed by Y-maze and short-term memory assessed by novel object recognition task were significantly improved by sunifiram treatment in OBX mice ... sunifiram ameliorates OBX-induced deficits of memory-related behaviors and impaired LTP in the hippocampal CA1 region via stimulation of glycine-binding site of NMDAR.
Moriguchi S, Tanaka T, Tagashira H, Narahashi T, Fukunaga K. · Behavioural Brain Research (2013)
RODENT MODEL: in olfactory-bulbectomized mice (a model of cholinergic memory impairment), oral sunifiram (0.01–1.0 mg/kg) improved Y-maze spatial reference memory and novel-object-recognition short-term memory
Sunifiram restored hippocampal LTP and normalized CaMKIIα and GluR1 (AMPA-subunit) phosphorylation, plus PKCα and NR1 (NMDA-subunit) phosphorylation, to control levels
The behavioural and biochemical rescue was blocked by an NMDA glycine-site inhibitor (gavestinel), confirming the glycine-site / CaMKII / PKC mechanism in vivo
Some of the compounds display good antiamnesic and procognitive activity, with higher potency than piracetam, and with a potency similar to the parent compounds.
Martini E, Salvicchi A, Ghelardini C, Manetti D, Dei S, Guandalini L, Martelli C, Melchiorre M, Cellai C, Scapecchi S, Teodori E, Romanelli MN. · Bioorganic & Medicinal Chemistry (2009)
MEDICINAL CHEMISTRY + RODENT TEST: amides and sulfonamides structurally related to DM-235 (sunifiram) and MN19 (sapunifiram) were synthesized and tested for cognition-enhancing activity in the mouse passive-avoidance test
Confirms sunifiram and its analogues as potent antiamnesic / procognitive nootropics in mice, more potent than piracetam
Characterizes the structure-activity relationship of the sunifiram chemotype — relevant to identity and mechanism, but entirely preclinical
A series of analogs of DM235 and MN19, characterized by rings with different size, have been prepared and evaluated for their nootropic activity in the mouse passive-avoidance test.
Guandalini L, Martini E, Di Cesare Mannelli L, Dei S, Manetti D, Scapecchi S, Teodori E, Ghelardini C, Romanelli MN. · Bioorganic & Medicinal Chemistry Letters (2012)
MEDICINAL CHEMISTRY + RODENT TEST: ring-size analogues of DM-235 (sunifiram) and MN19 were prepared and evaluated for nootropic activity in the mouse passive-avoidance test
Defines the optimal ring geometry (6–7-membered ring) for the DM-235 chemotype's anti-amnesic activity, refining the structure-activity relationship
Reinforces that sunifiram's procognitive activity is a robust but ANIMAL-only finding across a chemical series